Last reviewed · How we verify

NCT05836428

Biomarker Analysis in Post-COVID Patients

Completed Last updated 1 May 2023
What this trial tests

trial testing no intervention in Post-COVID-19 Syndrome in 48 participants. Completed in 26 April 2023.

Timeline
1 August 2020
Primary endpoint
26 April 2023
26 April 2023

Quick facts

Lead sponsorUniversity Hospital, Bonn
StatusCompleted
Study typeOBSERVATIONAL
Enrollment48
Start date1 August 2020
Primary completion26 April 2023
Estimated completion26 April 2023
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bonn

Who can join

Adults 18 to 80, any sex, with Post-COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Headache is one of the most common neurological manifestations of COVID-19. However, it is unclear whether chronic headache after the initial diagnosis, is associated with ongoing damage of the central nervous system. We investigate cpost-COVID-19 patients with persistent headache lasting longer than 3 weeks, to hospitalized acute COVID-19 patients with neurological symptoms and to other non-COVID-19 disease-controls. Readout are neurologial and glial biomarkers in CSF.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache.
    de Boni L, Odainic A, Gancarczyk N, Kaluza L, et al · · 2023 · cited 2× · PMID 37759276 · DOI 10.1186/s42466-023-00277-1

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Post-COVID-19 Syndrome

Currently open trials in the same condition.

Other University Hospital, Bonn trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05836428.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing